NOVEL AMPHOTERICIN B NANOPARTICLES FOR SYSTEMIC MYCOSIS

描述（来自申请人摘要的逐字描述）： 该计划是为了验证景天的新的双AcervateTM纳米颗粒配方， 药物、蛋白质和DNA的递送。当前药物的挑战之一 今天的发展是有效地提供化学和生物药物。 稳定生物活性成分的微粒和封装技术 并且使全身毒性最小化通常是困难和昂贵的， 大规模的Sedum Laboratories，Inc.发明了一种新的封装方法 基于两种带相反电荷的生物相容性聚合物的凝聚的方法 带电荷的药物或大分子。Bi-AcervateTM纳米颗粒包含 药物和大分子高效地在体内缓慢释放。 景天现在建议通过优化配方来验证这项技术， 最大限度地提高了阿替霉素B的掺入效率、稳定性和安全性。 两性霉素B是目前唯一有效的治疗严重系统性真菌感染的药物。 免疫功能低下患者的感染，但其使用受到严重的限制， 毒性脂质体制剂非常昂贵， 在一些医疗中心，候选BiAcervate制剂将 评价了体外和体内细胞毒性和抗真菌活性。 小鼠全身真菌感染实验模型。 拟定商业应用： Sedum建议通过开发先进的药物输送系统进入140亿美元的市场 两性霉素B的新纳米粒制剂。 这样会有更大的治疗指数 毒副作用比传统药物更少，更容易，更便宜， 比脂质体形式产生。 两性霉素B是治疗严重 系统性真菌感染，每年折磨10万名免疫功能低下的患者。

DESCRIPTION (Verbatim from Applicant's Abstract):The overall objective of this program is to validate Sedum's new Bi-AcervateTM nanoparticle formulation for delivery of drugs, proteins and DNA. One of the current challenges in drug development today is efficient delivery of chemical and biological medicines. Microparticle and encapsulation techniques that stabilize bioactive ingredients and minimize systemic toxicity often are difficult and expensive to produce at large scale. Sedum Laboratories, Inc. has developed a novel encapsulation method based on coacervation of two oppositely charged biocompatible polymers with a charged drug or macromolecule. Bi-AcervateTM nanoparticles incorporate drugs and macromolecules with high efficiency and release them slowly in vivo. Sedum now proposes to validate this technology by optimizing the formulation to maximize incorporation efficiency, stability and safety of amphotericin B. Amphotericin B is the only drug effective against severe systemic fungal infections in immunocompromised patients, but its use is limited by severe toxicity. Liposomal preparations are so expensive that they are not used routinely in some medical centers. Candidate BiAcervate formulations will be evaluated for cytotoxicity and anti-fungal activity in vitro and in an experimental model of systemic fungal infection in mice. PROPOSED COMMERCIAL APPLICATION: Sedum proposes to enter the $14B market for advanced drug delivery systems by developing a new nanoparticle formulation of Amphotericin B. This will have a greater therapeutic index and fewer toxic side effects than conventional drugs, and will be easier and less costly to produce than liposomal forms. Amphotericin B is the most effective drug for treating severe systemic fungal infections, which afflict 100,000 immunocompromised patients a year.